KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBITDA: 2010-2025

Historic EBITDA for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $28.4 million.

  • Rigel Pharmaceuticals' EBITDA rose 102.19% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 1151.72%. This contributed to the annual value of $24.2 million for FY2024, which is 218.06% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' EBITDA is $28.4 million, which was down 53.49% from $61.1 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year EBITDA high stood at $61.1 million for Q2 2025, and its period low was -$26.3 million during Q1 2022.
  • Its 3-year average for EBITDA is $9.6 million, with a median of $2.0 million in 2023.
  • Per our database at Business Quant, Rigel Pharmaceuticals' EBITDA crashed by 162.89% in 2022 and then spiked by 13,569.57% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' EBITDA (Quarterly) stood at -$21.4 million in 2021, then spiked by 109.71% to $2.1 million in 2022, then decreased by 5.44% to $2.0 million in 2023, then soared by 747.15% to $16.7 million in 2024, then soared by 102.19% to $28.4 million in 2025.
  • Its EBITDA was $28.4 million in Q3 2025, compared to $61.1 million in Q2 2025 and $12.8 million in Q1 2025.